Literature DB >> 30808435

Monitoring the Health Status of Mice with Bleomycin-induced Lung Injury by Using Body Condition Scoring.

Patrick M Cowley1, Clifford R Roberts2, Anthony J Baker2.   

Abstract

Well-defined, humane endpoints aid in monitoring animal health status during disease development. Body condition scoring (BCS) is a method for assessing health status in mouse studies where wasting and death are potential endpoints. Whether BCS is useful in monitoring animals with bleomycin-induced lung injury has not been reported. Body weight (BW) is a common humane endpoint for this model, but because the lungs increase in weight as BW decreases, the animal's true physical condition could be masked when using BW as the sole endpoint criterion. Therefore, our goal here was to assess the usefulness of BCS in monitoring health status in a mouse model of lung injury. Lung injury was caused by acute instil- lation of the fibrogenic antibiotic bleomycin into the lungs through the trachea. Male C57BL/6 mice received bleomycin (0.075 U) dissolved in saline or saline alone. Bleomycin instillation led to a doubling of lung weight and decreases in both BW and BCS, compared with saline instillation. The changes in BW and BCS were significantly correlated with lung weight. When the adjusted BW was used (corrected for the increase in lung weight), the correlation was unchanged, suggesting that the increase in lung weight did not significantly mask the decrease in BW. Bleomycin instillation caused decreases in both soleus and visceral epididymal fat masses. The change in BCS was significantly correlated with both soleus and VEF mass, suggesting that BCS is reflective of the systemic loss of muscle and fat mass. Our findings suggest that BW and BCS are significantly correlated to lung injury in the bleomycin model of lung fibrosis and that BCS is an appropriate alternative humane endpoint in this mouse model.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30808435      PMCID: PMC6464078          DOI: 10.30802/AALAS-CM-18-000060

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  20 in total

1.  Body condition scoring: comparing newly trained scorers and micro-computed tomography imaging.

Authors:  M E Easterly; C J Foltz; M J Paulus
Journal:  Lab Anim (NY)       Date:  2001-03       Impact factor: 12.625

2.  A role for ferrous ion and oxygen in the degradation of DNA by bleomycin.

Authors:  E A Sausville; J Peisach; S B Horwitz
Journal:  Biochem Biophys Res Commun       Date:  1976-12-06       Impact factor: 3.575

3.  Health Evaluation of Experimental Laboratory Mice.

Authors:  Tanya Burkholder; Charmaine Foltz; Eleanor Karlsson; C Garry Linton; Joanne M Smith
Journal:  Curr Protoc Mouse Biol       Date:  2012-06-01

4.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.

Authors:  J A Bjoraker; J H Ryu; M K Edwin; J L Myers; H D Tazelaar; D R Schroeder; K P Offord
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

Review 5.  Murine models of pulmonary fibrosis.

Authors:  Bethany B Moore; Cory M Hogaboam
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-11-09       Impact factor: 5.464

6.  PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.

Authors:  Anna R Hemnes; Ari Zaiman; Hunter C Champion
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-10-26       Impact factor: 5.464

7.  An improved simple method of mouse lung intubation.

Authors:  Kelvin D MacDonald; Herng-Yu Sucie Chang; Wayne Mitzner
Journal:  J Appl Physiol (1985)       Date:  2009-01-15

Review 8.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

9.  Quantification of Pulmonary Fibrosis in a Bleomycin Mouse Model Using Automated Histological Image Analysis.

Authors:  Jean-Claude Gilhodes; Yvon Julé; Sebastian Kreuz; Birgit Stierstorfer; Detlef Stiller; Lutz Wollin
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

10.  Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease.

Authors:  Ruoqi Peng; Sriram Sridhar; Gaurav Tyagi; Jonathan E Phillips; Rosario Garrido; Paul Harris; Lisa Burns; Lorena Renteria; John Woods; Leena Chen; John Allard; Palanikumar Ravindran; Hans Bitter; Zhenmin Liang; Cory M Hogaboam; Chris Kitson; David C Budd; Jay S Fine; Carla M T Bauer; Christopher S Stevenson
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more
  5 in total

1.  Pivotal role of micro-CT technology in setting up an optimized lung fibrosis mouse model for drug screening.

Authors:  Zahra Khalajzeyqami; Andrea Grandi; Erica Ferrini; Francesca Ravanetti; Ludovica Leo; Martina Mambrini; Luciana Giardino; Gino Villetti; Franco Fabio Stellari
Journal:  PLoS One       Date:  2022-06-15       Impact factor: 3.752

2.  Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice.

Authors:  Nan Ju; Hiroki Hayashi; Munehisa Shimamura; Satoshi Baba; Shota Yoshida; Ryuichi Morishita; Hiromi Rakugi; Hironori Nakagami
Journal:  Sci Rep       Date:  2022-07-21       Impact factor: 4.996

3.  Histone deacetylase 3 promotes alveolar epithelial-mesenchymal transition and fibroblast migration under hypoxic conditions.

Authors:  Sung Hwan Jeong; Eun Suk Son; Young Eun Lee; Sun Young Kyung; Jeong-Woong Park; Se-Hee Kim
Journal:  Exp Mol Med       Date:  2022-07-08       Impact factor: 12.153

4.  Cymbopogon winterianus Essential Oil Attenuates Bleomycin-Induced Pulmonary Fibrosis in a Murine Model.

Authors:  Lívia A Tavares; Allan A Rezende; Jymmys L Santos; Charles S Estevam; Ana M O Silva; Jaderson K Schneider; John L S Cunha; Daniela Droppa-Almeida; Ivan J Correia-Neto; Juliana C Cardoso; Patricia Severino; Eliana B Souto; Ricardo L C de Albuquerque-Júnior
Journal:  Pharmaceutics       Date:  2021-05-09       Impact factor: 6.321

5.  Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis.

Authors:  Mark R Jackson; Katrina Stevenson; Sandeep K Chahal; Emer Curley; George E Finney; Rodrigo Gutierrez-Quintana; Evarest Onwubiko; Angie Rupp; Karen Strathdee; Karin Williams; Megan K L MacLeod; Charles McSharry; Anthony J Chalmers
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-31       Impact factor: 7.038

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.